Pharmaceutical Form: Solution for injection

DRUG3 trials

Sponsors

Rigshospitalet, Baxter Innovations GmbH

Conditions

H5N1 vaccination in healthy subjects (adult and elderly population) and in specified risk groups (chronically ill, transplant and HIV patients).H5N1 vaccination with a single Prime-Boost Vaccination schedule in healthy subjects aged 18 to 59 years. MedDRA version: 9.1 Level: LLT Classification code 10059430 Term: Influenza immunizationMucositis and systemical inflammationwhich is a treatment-related complication after treatment with high-dose chemotherapy

Phase 2

Semaglutide Treatment for Prevention of Toxicity in High-dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation – a randomized, double-blind, placebo-controlled, investigator-initiated study

RecruitingCTIS2022-502139-20-00

RigshospitaletMucositis and systemical inflammation, which is a treatment-related complication after treatment with high-dose chemotherapy

Start: 2024-09-09Target: 40Updated: 2025-06-18

Phase 3

An Open-Label Phase III Study to Assess the Safety and Immunogenicity of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in an Adult and Elderly Population as well as in Specified Risk Groups - Phase III Study of a H5N1 Vaccine in Adults, Elderlys, and Specified Risk Groups.

Active, not recruitingEUCTR2008-000558-11-AT

Baxter Innovations GmbHH5N1 vaccination in healthy subjects (adult and elderly population) and in specified risk groups (chronically ill, transplant and HIV patients).

Start: 2008-06-26Target: 3560Updated: 2019-06-30

Unknown Phase

An Open Label Phase I/II Study to Assess the Immunogenicity and Safety of a Single Prime-Boost Vaccination Schedule with a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in Healthy volunteers Aged 18 to 59 Years - Phase I/II Study of a H5N1 Vaccine

Active, not recruitingEUCTR2008-005133-30-AT

Baxter Innovations GmbHH5N1 vaccination with a single Prime-Boost Vaccination schedule in healthy subjects aged 18 to 59 years. MedDRA version: 9.1 Level: LLT Classification code 10059430 Term: Influenza immunization

Start: 2009-01-22Target: 230Updated: 2012-03-19

Related Papers

Semaglutide treatment for PRevention Of Toxicity in high-dosE Chemotherapy with autologous haematopoietic stem-cell Transplantation (PROTECT): study protocol for a randomised, double-blind, placebo-controlled, investigator-initiated study

BMJ Open2024-10-014 citations